Year archive

Xspray Pharma — 2021 filings

All 39 regulatory filings released by Xspray Pharma (XSPRAY) in 2021, sourced directly from the official regulator.

39 Filings

2021 Period

2021 filings (39)

Filing	Released	Lang
Number of shares and votes in Xspray Pharma Declaration of Voting Results & Voting Rights Announcements	2021-11-30	English
Antal aktier och röster i Xspray Pharma Share Issue/Capital Change	2021-11-30	Swedish
Major Shareholding Notification 2021 Major Shareholding Notification	2021-11-08	English
Xspray Pharma completes a directed new share issue to Flerie Invest, raising approximately SEK 100 million Share Issue/Capital Change	2021-11-08	English
Xspray Pharma genomför en riktad nyemission till Flerie Invest och tillförs cirka 100 miljoner kronor Share Issue/Capital Change	2021-11-08	Swedish
Interim / Quarterly Report 2021 Interim / Quarterly Report 9M 2021	2021-10-26	Swedish
Interim / Quarterly Report 2021 Interim / Quarterly Report Q3 2021	2021-10-26	English
Xspray Pharma brings forward publication of the Q3 interim report Report Publication Announcement	2021-10-25	English
Xspray Pharma tidigarelägger publicering av delårsrapport för tredje kvartalet Report Publication Announcement	2021-10-25	Swedish
Xspray Pharmas valberedning inför årsstämman 2022 AGM Information	2021-10-15	Swedish
Xspray Pharma’s Nomination Committee for the Annual General Meeting 2022 AGM Information	2021-10-15	English
Xspray Pharma har erhållit resultat från bioekvivalensstudier med HyNap-Dasa ANDA och väljer att fokusera på den förbättrade produkten Dasynoc™ Regulatory Filings	2021-10-13	Swedish
Xspray Pharma has obtained results from bioequivalence studies with HyNap-Dasa ANDA and decides to focus on its improved dasatinib product, Dasynoc™ Regulatory Filings	2021-10-13	English
Interim / Quarterly Report 2021 Interim / Quarterly Report Q2 2021	2021-08-06	Swedish
Interim / Quarterly Report 2021 Interim / Quarterly Report Q2 2021	2021-08-06	English
Xspray Pharma meddelar uppnådd bioekvivalens jämfört med referensprodukten från registreringsgrundande studie med HyNap-Dasa 505(b)(2) Regulatory Filings	2021-07-28	Swedish
Xspray Pharma announces achievement of bioequivalence compared with reference product from bioequivalence study with HyNap-Dasa 505(b)(2) Regulatory Filings	2021-07-28	English
Kommuniké från årsstämma i Xspray Pharma AB (publ) AGM Information	2021-05-20	Swedish
Bulletin from the annual general meeting of Xspray Pharma AB (publ) AGM Information	2021-05-20	English
Interim / Quarterly Report 2021 Interim / Quarterly Report Q1 2021	2021-05-06	Swedish
Interim / Quarterly Report 2021 Interim / Quarterly Report Q1 2021	2021-05-06	English
Kallelse till årsstämma i Xspray Pharma AB (publ) AGM Information	2021-04-20	Swedish
Notice of annual general meeting of Xspray Pharma AB (publ) AGM Information	2021-04-20	English
Xspray Pharma meddelar resultat från två bioekvivalensstudier med justerad tablettformulering av HyNap-Dasa (ANDA) Regulatory Filings	2021-04-08	Swedish
Xspray Pharma announces the results of two bioequivalence studies with adjusted tablet formulation of HyNap-Dasa (ANDA) Regulatory Filings	2021-04-08	English
Audit Report / Information 2020 Audit Report / Information FY 2020	2021-03-19	Swedish
Annual Report 2020 Annual Report FY 2020	2021-03-19	English
Interim / Quarterly Report 2020 Interim / Quarterly Report Q4 2020	2021-02-25	Swedish
Interim / Quarterly Report 2020 Interim / Quarterly Report Q4 2020	2021-02-25	English
Valberedningen föreslår Anders Ekblom till ny ordförande i Xspray Pharma Board/Management Information	2021-02-17	Swedish
Nomination Committee proposes Anders Ekblom as new Chairman of the Board in Xspray Pharma Board/Management Information	2021-02-17	English
Antal aktier och röster i Xspray Pharma Declaration of Voting Results & Voting Rights Announcements	2021-01-29	Swedish
Number of shares and votes in Xspray Pharma Declaration of Voting Results & Voting Rights Announcements	2021-01-29	English
Warrant holders exercise all warrants within the framework of the incentive program Share Issue/Capital Change	2021-01-26	English
Optionsinnehavare utnyttjar samtliga teckningsoptioner inom ramen för incitamentsprogram Share Issue/Capital Change	2021-01-26	Swedish
Xspray Pharmas study with modified formulation of HyNap-Dasa has now started Regulatory Filings	2021-01-22	English
Xspray Pharmas studie med modifierad formulering av HyNap-Dasa har nu startats Regulatory Filings	2021-01-22	Swedish
Xspray Pharma announces results from additional bioequivalence study and provides update regarding upcoming regulatory applications for ANDA and 505(b)(2) Regulatory Filings	2021-01-14	English
Xspray Pharma meddelar resultat från extra bioekvivalensstudie och lämnar uppdatering avseende kommande registreringsansökningar för ANDA respektive 505(b)(2) Regulatory Filings	2021-01-14	Swedish